Friday, January 22, 2021

Avidity Biosciences Names Chief Technical Officer

La Jolla-based Avidity Biosciences, a biopharmaceuticals company which is developing oligonucleotide-based therapies, said this week that it as named W. Michael Flanagan, Ph.D., as its Chief Technical Officer. Dr. Flanagan was most recently Senior Director and Project Team Leader, Oncology and Immunology for Genentech, and also previously served at Sunesis Pharmaceuticals, Gilead Sciences, and Merck & Co. Avidity's lead product candidate, is aimed at treating myotonic dystrophy type 1, and its other muscle programs are focused on the treatment of Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, Pompe disease and muscle atrophy.

---